denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Education Program
Session: What Are the Advances in Myeloproliferative Neoplasms Affecting Management?
Hematology Disease Topics & Pathways:
Research, clinical trials, Translational Research, Clinical Practice (Health Services and Quality), MPN, Clinical Research, Combination therapy, Chronic Myeloid Malignancies, drug development, Diseases, Therapies, therapy sequence, Myeloid Malignancies
Session: What Are the Advances in Myeloproliferative Neoplasms Affecting Management?
Hematology Disease Topics & Pathways:
Research, clinical trials, Translational Research, Clinical Practice (Health Services and Quality), MPN, Clinical Research, Combination therapy, Chronic Myeloid Malignancies, drug development, Diseases, Therapies, therapy sequence, Myeloid Malignancies
Sunday, December 10, 2023, 9:30 AM-10:45 AM
Disclosures: Gill: BMS: Consultancy; Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Research Funding; Pfizer: Consultancy, Other: Conference support; GSK: Consultancy; PharmaEssentia: Consultancy, Other: Conference Support, Research Funding; Novartis: Consultancy, Other: Conference Support, Research Funding.
OffLabel Disclosure: The use of pegylated interferon alfa 2A and ropeginterferon alfa 2b.
See more of: What Are the Advances in Myeloproliferative Neoplasms Affecting Management?
See more of: Education Program
See more of: Education Program